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Background: Ambulatory blood pressure (BP) is more sensitive than ofﬁ  ce BP and is highly 
correlated with the left ventricular mass (LVM) of hypertensive patients with left ventricular 
hypertrophy (LVH).
Methods: In this prospectively designed ancillary study of the PICXEL trial, the effects of 
ﬁ  rst-line combination perindopril/indapamide on ambulatory BP were compared with those 
of monotherapy with enalapril in 127 patients. Hypertensive patients with LVH received once 
daily either perindopril 2 mg/indapamide 0.625 mg (n = 65) or enalapril 10 mg (n = 62) for 52 
weeks. Dose adjustments were allowed for uncontrolled BP. Twenty-four-hour ambulatory BP 
and echocardiographic parameters were measured at baseline, week 24, and week 52.
Results: At study end, both treatments signiﬁ  cantly improved ambulatory BP compared with 
baseline (p  0.01). Perindopril/indapamide treatment reduced 24-hour and daytime systolic 
BP (SBP) and pulse pressure (PP) signiﬁ  cantly more than enalapril treatment (p < 0.01). No 
signiﬁ  cant between-group differences were noted for diastolic BP (DBP) or for night-time 
measurements. Trough/peak ratios were higher with perindopril/indapamide than with enalapril 
(88.5 vs 65.8 for SBP and 86.7 vs 63.9 for DBP, respectively). The global smoothness index 
was higher with perindopril/indapamide than with enalapril (6.6 vs 5.2 for SBP and 5.6 vs 4.9 
for DBP, respectively). With perindopril/indapamide treatment, LVM index was signiﬁ  cantly 
reduced (−9.1 g/m2 from baseline; p vs baseline <0.001). More patients required dose increases 
with enalapril (87%) than with perindopril/indapamide (71%). No unusual safety elements 
were noted.
Conclusions: First-line perindopril/indapamide combination decreased ambulatory SBP and 
PP, and LVM more effectively than enalapril.
Keywords: left ventricular hypertrophy, ambulatory blood pressure monitoring, perindopril, 
indapamide, enalapril
Introduction
Left ventricular hypertrophy (LVH) and organ damage resulting from hypertension 
can place patients at risk for cardiovascular events, such as myocardial infarction, heart 
failure, and stroke (Casale et al 1986; Koren et al 1991; Ciardullo et al 2004). Daily 
blood pressure variations, calculated from ambulatory blood pressure recordings, are 
increasingly being considered as signiﬁ  cant contributors to such end organ damage 
and cardiovascular risk (Frattola et al 1993; Kikuya et al 2000; Parati 2005).
In a study of 1542 subjects, a signiﬁ  cant linear relation was noted between 
cardiovascular mortality risk and daytime systolic blood pressure (SBP) variations 
(Kikuya et al 2000). In addition, in several studies, 24-hour ambulatory BP 
measurements were more sensitive predictors of cardiovascular morbidity and mortality 
than conventional ofﬁ  ce BP measurements (Ohkubo et al 1997; Verdecchia et al 1998; 
Staessen et al 1999). Thus, regression of LVH, which has been associated with improved Vascular Health and Risk Management 2007:3(4) 372
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cardiovascular prognosis (Anon. 2004), may be more closely 
correlated with reductions in ambulatory BP than with 
reductions in ofﬁ  ce blood pressure (Omboni et al 1998).
The renin-angiotensin-aldosterone system (RAAS) is 
implicated in the development of hypertension and LVH 
(Matsumura et al 2006). Consistent with this understand-
ing, meta-analyses have found that RAAS inhibitors are 
more effective than other types of treatment in reducing left 
ventricular mass (LVM) (Dahlöf et al 1992; Schmieder et al 
1996; Klingbeil et al 2003). As diuretics have been shown 
to reduce ventricular diameter and angiotensin-converting 
enzyme (ACE) inhibitors to reduce wall thickness, an ACE 
inhibitor combined with a diuretic may be more effective than 
an ACE inhibitor alone (Dahlöf et al 1992). Indeed, ﬁ  rst-line 
combination perindopril/indapamide has been shown in the 
52-week PICXEL study to be more effective in reducing 
LVM and ofﬁ  ce BP in patients with LVH than treatment with 
ACE inhibitor monotherapy enalapril (Dahlöf et al 2005).
Perindopril/indapamide treatment has also been shown 
to reduce 24-hour ambulatory BP and smooth BP proﬁ  les in 
patients with uncomplicated essential hypertension (Mallion 
et al 2004). Consequently, to investigate further the effect of 
perindopril/indapamide on 24-hour BP variations in patients 
with LVH and to assess further the differences between 
ﬁ  rst-line combination therapy perindopril/indapamide and 
monotherapy enalapril, ambulatory BP was monitored in a 
subset of patients enrolled in the PICXEL study.
Methods
This study is an ancillary study of the previously published, 
randomized, double-blind, parallel-group, PICXEL study 
performed from June 1999 to March 2002 (Gosse et al 2002; 
Dahlöf et al 2005). This analysis will focus on materials and 
methods pertinent to this substudy, which was prospectively 
designed to measure ambulatory BP.
Patient population
Patients enrolled in the PICXEL study (n = 679) were given 
the option to participate concomitantly in this ancillary 
study. No additional or speciﬁ  c entry criteria were speciﬁ  ed. 
The main inclusion criteria for PICXEL were essential 
systolic and diastolic or isolated systolic hypertension 
(140 mmHg  sitting SBP <210 mmHG) and LVM index 
([LVMI] >120 g/m² for men and >100 g/m2 for women). The 
main exclusion criteria were severe hypertension (diastolic 
BP [DBP] 115 mmHg and/or SBP 210 mmHg), and 
secondary or complicated hypertension (with the exception 
of LVH). 
Study design
As in PICXEL, after a 4-week placebo run-in period, patients 
received either combination perindopril 2 mg/indapamide 
0.625 mg or enalapril 10 mg once a day for 52 weeks (Gosse 
et al 2002; Dahlöf et al 2005). Dose adjustments to combina-
tion perindopril 4 mg/indapamide 1.25 mg or enalapril 20 mg 
and then to combination perindopril 8 mg/indapamide 2.5 mg 
or enalapril 40 mg were requested if BP was not controlled. 
Adjustments were based on ofﬁ  ce BP measurements and 
speciﬁ  c predeﬁ  ned criteria (Gosse et al 2002; Dahlöf et al 
2005). Adjustments took place at ofﬁ  ce visits at weeks 6, 12, 
24, and 36. Treatment compliance was assessed during the 
double-blind treatment period by counting returned unused 
capsules.
Ambulatory BP
Patients were ﬁ  tted between 8 AM and 11 AM with a non-
invasive automated blood pressure recorder at baseline 
(week 0), week 24, and study end (week 52). Use of a recorder 
that met the validation requirements of the British Hyperten-
sion Society and/or American Association for the Advance-
ment of Medical Instrumentation was recommended. Drug 
intake took place within 30 minutes after ﬁ  tting. Recordings 
were performed every 15 minutes during the daytime (7 AM 
to 10 PM), every 30 min during the night-time (10 PM to 
7 AM), and for at least 25 hours.
To ensure data quality, all ambulatory BP record-
ings were blindly reviewed by a central ambulatory BP 
monitoring (ABPM) committee. The prospectively estab-
lished validation criteria were: ambulatory BP needed to 
have been recorded for 25 hours after dosing; 75% of 
each recording was eligible for analysis; no two consecu-
tive hourly average blood pressure values were missing; 
both 2nd to 8th and 23rd to 24th averages were present; 2 
valid measurements per hour over the daytime period and 1 
per hour in the night-time period were available; a baseline 
recording and at least 1 post-baseline recording was avail-
able. The following artifacts were systematically excluded: 
any DBP > SBP; SBP <60 mmHg; SBP >250 mmHg; 
DBP <40 mmHg; DBP >150 mmHg; a blood pressure dif-
ferential (SBP – DBP) <10 mmHg with a SBP >110 mmHg. 
Non-valid recordings could be repeated within a week.
Daytime, night-time, and 24-hour means were calculated 
for ambulatory SBP, DBP, and PP. Pulse pressure was 
deﬁ  ned as SBP – DBP. Two-hourly means, global trough/
peak ratio, and global smoothness index were also calcu-
lated. The trough (minimum treatment effect/highest BP) 
was deﬁ  ned as the 12th 2-hourly mean (just before the next Vascular Health and Risk Management 2007:3(4) 373
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dose). The peak (maximum treatment effect/lowest BP) was 
deﬁ  ned as the lowest reading from the 2nd to the 5th 2-hourly 
mean. The smoothness index was deﬁ  ned as the mean of the 
hourly mean changes from baseline to study end divided by 
its standard deviation.
Other variables
Echocardiography was performed at week –4, week 0, week 
24, and week 52 (Wend). Patients were examined in the left 
lateral supine position after 15 minutes of rest. Left ven-
tricular mass, end-diastolic left ventricular internal diameter 
(LVIDd), end-diastolic left ventricular posterior wall thick-
ness (PWTd), and end-diastolic interventricular septal wall 
thickness (IVSTd) were measured. Echocardiograms were 
read by the Central Echocardiography Committee using a 
Iô 3.2 unit (IôDP, Paris, France). Data presented are the 
results from the ﬁ  nal central blinded reading.
Ofﬁ  ce SBP and DBP were measured by mercury sphyg-
momanometer at each visit according to the European Society 
of Hypertension guidelines.
Safety
The safety assessment was based on the incidence of adverse 
events among all the patients participating in the PICXEL 
study.
Statistics
This ancillary study was exploratory; no sample size 
estimate was performed. The efﬁ  cacy population included 
all randomized patients having taken at least one dose 
of study treatment, with a valid ambulatory reading at 
baseline and at least one valid ambulatory reading post-
baseline.
Descriptive statistics were provided for all criteria. 
Effects of treatment with perindopril/indapamide vs enalapril 
on ambulatory parameters and sphygmomanometer BPs were 
compared using an analysis of covariance (α = 2.5% with a 
95% conﬁ  dence interval [CI]). Analyses were adjusted for 
the baseline value and used the last observation post-baseline. 
The signiﬁ  cance of the changes from baseline in ambula-
tory parameters and sphygmomanometer BPs was tested in 
each group, without adjustment, using the last observation 
post-baseline and a one tailed Student’s t-test for dependent 
samples (α = 2.5% with a 95% CI).
The between-group differences perindopril/indapamide 
vs enalapril on LVMI were compared after adjustment for 
baseline value and gender using an analysis of covariance
(α = 5% with a 95% CI). The within-group changes from 
baseline in LVMI were tested, without adjustment, using 
the last observation post-baseline and a one-tailed Student’s 
t-test for dependent samples (α = 2.5% with a 95% CI). 
Complementary analyses were performed to assess between-
group differences in LVMI at baseline (using a two-sided 
Student’s t-test; α = 5%) and to compare dose increases 
between groups (using a Chi-square test).
The multiple linear regression was performed using a 
stepwise selection method. 
The statistical analysis was performed using SAS version 
8.2 and Statgraphics version 5.0.
Ethics
The study was conducted in accordance with the ethical 
principles stated in the 1964 Declaration of Helsinki and 
revised in Somerset West in 1996 and in Edinburgh in 
2000. The protocol was approved by the independent Ethics 
Committees of each country. All the patients gave written 
informed consent.
Results
One hundred and forty-six patients from a total of 28 
centers in 7 countries participated in this ancillary study. 
The efﬁ  cacy population of 127 subjects was deﬁ  ned as all 
randomized patients who took as least one dose of studied 
treatment with a valid ABPM at M0 performed before M0 
visit and at least one valid ABPM post-baseline. The efﬁ  cacy 
population was made up of 65 perindopril/indapamide-
treated patients and 62 enalapril-treated patients. Study 
groups were well balanced in terms of demographics and 
baseline characteristics (Table 1). Patients were on average 
55 ± 9 years of age; 11% presented with a complication 
other than LVH such as retinopathy or hypertensive 
encephalopathy, 68% had a family history of hypertension; 
and most patients (88.2%) had received at least one previous 
treatment for hypertension. No clinically relevant differences 
were observed between groups for baseline office and 
ambulatory BP measurements and for baseline LVMI (Table 
1). There were signiﬁ  cant relationships between baseline 
LVMI and ambulatory SBP, DBP, and PP (correlation 
coefﬁ  cients from 0.20 to 0.30, p < 0.05). Relationships 
between baseline LVMI and ofﬁ  ce SBP and PP were non-
signiﬁ  cant (correlation coefﬁ  cients less than 0.12, NS) and 
signiﬁ  cant only for ofﬁ  ce DBP (correlation coefﬁ  cient 0.20, 
p < 0.05). Multiple linear regression shows that factors with 
an impact on baseline LVMI are sex (p < 0.0001), nocturnal 
mean SBP (p = 0.0018) and BMI (p = 0.1190) (R² = 0.23, 
p < 0.0001) (Table 2).Vascular Health and Risk Management 2007:3(4) 374
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Patients were exposed to treatment for a mean of 365 ± 19 
days and 360 ± 44 days in the perindopril/indapamide and 
enalapril groups, respectively. Overall compliance was 
99.8 ± 3.4% and 100.5 ± 3.3% in the perindopril/indapamide 
and enalapril groups, respectively.
Dose increases were required significantly more 
frequently in the enalapril group than in the perindopril/
indapamide group at week 24 (80.6% vs 61.6%, respectively; 
p = 0.03). At week 52, the same tendency was observed but the 
difference was not statistically signiﬁ  cant (87.1% vs 70.8%, 
respectively; p = 0.08).
Efﬁ  cacy
At study end, treatment of both groups with perindopril/
indapamide and enalapril significantly reduced office 
(Table 3) and ambulatory SBP, DBP, and PP measured over 
24 hours, during the daytime, and during the night-time (p vs 
baseline 0.01; Figure 1).
Decreases in 24-hour and daytime ambulatory SBP and 
PP were signiﬁ  cantly greater in the perindopril/indapamide 
group than in the enalapril group. Between-group differences 
of 6.1 ± 2.4 mmHg and 4.1 ± 1.6 mmHg were noted for 
24-hour SBP and PP, respectively (p vs enalapril <0.01; 
Figure 1A). Between-group differences of 6.0 ± 2.5 mmHg and 
4.3 ± 1.6 mmHg were noted for daytime SBP and PP, respec-
tively (p vs enalapril <0.01; Figure 1B). Decreases in night-
time ambulatory SBP and PP were greater in the perindopril/
indapamide group than in the enalapril group, but differences 
were not statistically signiﬁ  cant (Figure 1C). Similar results 
were recorded for 24-hour SBP measurements at week 24 
(data not shown).
There was a tendency towards greater decreases in 
ambulatory DBP in the perindopril/indapamide group than 
in the enalapril group. These differences, however, were not 
signiﬁ  cant (between-group differences of 2.1 ± 1.5 mmHg, 
1.8 ± 1.5 mmHg, and 2.2 ± 1.7 for 24-hour, daytime, and 
night-time measurements, respectively; Figure 1). Similar 
results were recorded for 24-hour measurements at week 24 
(data not shown).
At baseline, circadian variations of SBP, DBP, and 
PP, averaged every 2 hours over the 24-hour period, were 
similar for both groups. At study end, the circadian variation 
chronograms of SBP, DBP, and PP were lower in the 
perindopril/indapamide group than in the enalapril group 
throughout the 24-hour period (Figure 2).
Table 1 Demographics, baseline blood pressure measurementsa 
and echocardiographic parametersb
   Perindopril/  Enalapril
   indapamide 
    n = 65  n = 62
Demographics    
 Age,  years    55  ± 9  56 ± 10
  Gender, % male    38.5  45.2
  Ethnic origin, % Caucasian  92  95
  Body mass index, kg/m2 27  ± 2.9  27 ± 3.2
Ofﬁ  ce BP      
 SBP,  mmHg    166.7  ± 14.4  166.3 ± 14.0
 DBP,  mmHg    100.1  ± 8.8  98.8 ± 9.3
 PP,  mmHg    66.6  ± 11.7  67.5 ± 12.2
Ambulatory BP      
Over 24 hours   SBP, mmHg   152.0 ± 15.2  151.8 ± 16.0
  DBP, mmHg   91.9 ± 10.1  91.0 ± 11.7
  PP, mmHg   60.1 ± 11.9  60.8 ± 11.9
Daytime   SBP, mmHg  155.1 ± 14.6  154.6 ± 15.5
 DBP,  mmHg  94.6  ± 10.2  93.7 ± 11.9
 PP,  mmHg  60.5  ± 12.1  60.9 ± 11.6
Night-time   SBP, mmHg  143.1 ± 19.2  143.2 ± 19.9
 DBP,  mmHg  84.1  ± 12.0  82.8 ± 12.3
 PP,  mmHg  59.1  ± 13.1  60.4 ± 13.8
Echocardiographic parameter
 LVMI,  g/m2   133.2  ± 24.0  136.5 ± 34.5
aMeasurements are expressed as means ± SD or percentages. 
bDemographics were recorded at the run-in visit (week –4); baseline BP and echo-
cardiographic measurements were performed at the baseline visit (week 0) or at 
the run-in visit if baseline data were missing. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; LVMI, left 
ventricular mass index; PP, pulse pressure; SBP, systolic blood pressure.
Table 2 Inﬂ  uencing factors of left ventricular mass index at 
baseline
Variable at baseline  Parameter  Standard  p value  Partial
 estimate  error    R²
Sex –21.58  5.18  <0.0001  0.1316
Nocturnal mean SBP   0.43  0.14  0.0018  0.0830
BMI 1.29  0.82  0.1190  0.0176
Multiple linear regression: R² 0.2321, p < 0.0001.
Abbreviations: BMI, body mass index.
Table 3 Change in ofﬁ  ce blood pressure between baseline and 
study end
 Perindopril/  Enalapril  p  between-
 indapamide    group
 n  = 65  n = 62  difference†
SBP, mmHg  −28.1 ± 16.5*  −18.7 ± 17.2*  0.0002
DBP, mmHg  −12.3 ± 8.4*  −8.9 ± 11.1*  0.039
PP, mmHg  −15.8 ± 12.6*  −9.8 ± 12.2*  0.0002
Measurements are expressed as means ± SD. *p vs baseline 0.0001. †α = 2.5%.
Abbreviations: DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic 
blood pressure.Vascular Health and Risk Management 2007:3(4) 375
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Figure 1 Changes in ambulatory blood pressure after 52 weeks of treatment with perindopril/indapamide (n = 65) or enalapril (n = 62). A. Over 24 hours; B. Daytime; 
C. Night-time. Mean changes from baseline and standard deviations in parentheses are presented. *p vs baseline 0.01; **p vs baseline 0.001, †p vs enalapril <0.01.
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure.Vascular Health and Risk Management 2007:3(4) 376
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Figure 2 Variations in blood pressure over 24 hours in perindopril/indapamide (n = 65) and enalapril (n = 62). A. SBP; B. DBP; C. PP. Mean baseline and end-of-study ambu-
latory blood pressure calculated every 2 hours are plotted. 
Abbreviations: DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
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For SBP and DBP, the global trough/peak ratio tended to 
be higher after perindopril/indapamide treatment than after 
enalapril treatment (88.5 vs 65.8 for SBP and 86.7 vs 63.9 
for DBP). The absolute value of the global smoothness 
index tended to be higher after perindopril/indapamide treat-
ment than after enalapril treatment (6.6 vs 5.2 for SBP and 
5.6 vs 4.9 for DBP respectively; Table 4).
At study end, mean LVMI signiﬁ  cantly decreased 
compared to baseline after perindopril/indapamide treat-
ment (−9.1 ± 21.6 g/m²; p vs baseline <0.001), but not after 
enalapril treatment (+1.8 ± 24.8 g/m²; p vs baseline = 0.7). 
The adjusted difference between groups was signiﬁ  cant 
(p vs enalapril = 0.004). Slight reductions in LVIDd, 
PWTd, and IVSTd were also observed in the perindopril/
indapamide group, whereas slight increases were noted 
in the enalapril group (data not shown). The correlations 
between changes (end – baseline) in ambulatory blood 
pressure and in LVMI (over 24 hours, daytime, night-time) 
were signiﬁ  cant in the enalapril group (correlation coef-
ﬁ  cients from 0.30 to 0.40, p < 0.05) and non signiﬁ  cant 
in the perindopril/indapamide group (correlation coefﬁ  -
cients less than 0.07, NS; Figures 3 and 4). Multiple linear 
regression shows that the factors with an impact on LVMI 
change during the follow up of this study are baseline 
LVMI (p < 0.0001) and treatment group (p = 0.0046), 
(R² = 0.17; p < 0.0001) (Table 5).
Safety
Safety in this substudy was similar to that of the main 
PICXEL study (Dahlöf et al 2005). In the main PICXEL 
study (679 patients) adverse events related to treatment 
occurred in 17.3% of the perindopril/indapamide group and 
in 15.7% of the enalapril group.
Discussion
In this 1-year study of hypertensive patients with LVH, 
treatment with the ﬁ  rst-line combination perindopril/inda-
pamide was signiﬁ  cantly more effective in reducing ambu-
latory SBP and PP over 24 hours and during the daytime 
than treatment with enalapril. These data, which were, 
overall, consistent with those recorded in the ambulatory 
BP REASON substudy (Mallion et al 2004), suggest that 
perindopril/indapamide has a sustained, antihypertensive 
effect that attenuates blood pressure over a full 24 hours. In 
addition, the data suggesting a decrease in LVH, as measured 
by LVMI, are consistent with those recorded in the main 
PICXEL and in the REASON echocardiography study (De 
Luca et al 2004; Dahlöf et al 2005).
Twenty-four-hour monitoring provides a snapshot of 
the effect of treatment on BP variations over the course of a 
day. Several studies have suggested that these ﬂ  uctuations 
contribute signiﬁ  cantly to cardiovascular morbidity and 
mortality (Frattola et al 1993; Kikuya et al 2000). A treat-
ment that reduces the difference between BP troughs and 
peaks is likely to improve cardiovascular outcomes (Parati 
2005). A high smoothness index (1), for example, has 
been correlated with positive changes in carotid artery wall 
thickness (Rizzoni et al 2001). Results of this study showed 
that perindopril/indapamide treatment reduced BP peaks and 
troughs and smoothed the BP curve (smoothness index 5) 
compared with baseline. Although this study was not 
designed to assess cardiovascular outcomes, the decrease in 
LVMI suggests an improvement in cardiovascular health.
Increasing evidence suggests that ofﬁ  ce and ambulatory 
PP and SBP are independent predictors of cardiovascular 
disease (Verdecchia et al 1998; Franklin et al 1999; Millar 
et al 1999; Staessen et al 1999). This understanding of 
hypertension together with the data presented here suggest 
that perindopril/indapamide, by its greater control of SBP 
and PP (ambulatory and ofﬁ  ce), may reduce cardiovascular 
risk more signiﬁ  cantly than enalapril.
In this study, not only was ﬁ  rst-line combination therapy 
with perindopril/indapamide more effective than monotherapy 
with enalapril, but fewer perindopril/indapamide-treated pa-
tients required dose increases. These data are consistent with the 
Table 4 Global trough/peak ratio and smoothness index at 
study end
   Perindopril/  Enalapril
   indapamide 
    n = 65  n = 62
Global trough/peak ratio
SBP    Trough change from   –14.9  –6.8
    baseline,  mmHg
      Peak change from   –16.8  –10.3
    baseline,  mmHg
    Global  trough/  88.5  65.8
    peak  ratio,  %   
DBP   Trough change from   –7.7  –4.1
    baseline,  mmHg
      Peak change from   –8.9  –6.5
    baseline,  mmHg
    Global  trough/  86.7  63.9
    peak  ratio,  %   
Global smoothness index  
    SBP   6.6  5.2
    DBP    5.6  4.9
Abbreviations: DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic 
blood pressure.Vascular Health and Risk Management 2007:3(4) 378
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fact that monotherapies are often less effective than combina-
tion therapies in achieving BP control (Dickerson et al 1999; 
Hansson et al 1998). Enalapril, as monotherapy, does not target 
as many pathways and feedback mechanisms as ACE inhibitor/
diuretic combination therapy with perindopril/indapamide. In 
comparative clinical trials, the combination perindopril/indap-
amide was more effective than atenolol, losartan, amlodipine, or 
enalapril monotherapy (Chanudet and de Champvallins 2001, 
Mogensen et al 2003; De Luca et al 2004; Mallion et al 2004; 
Mourad et al 2004; Dahlöf et al 2005).
In this ancillary study, patients were comparably distributed 
among treatment groups and baseline characteristics were 
similar. The small variations noted between groups were neither 
statistically signiﬁ  cant nor considered clinically relevant. The 
difference between the ambulatory and ofﬁ  ce BP measurements 
can be explained by the subjective nature and the observed bias 
Figure 3 Relationship between mean systolic blood pressure over 24 hours (mmHg) change (Wend –   W0) and left ventricular mass index change in enalapril group 
(n = 62). ρ: Pearson correlation coefﬁ  cient.
Figure 4 Relationship between mean SBP over 24 hours (mmHg) change (Wend – W0) and left ventricular mass index change (Wend – baseline) in perindopril/indapamide 
group (n = 65). ρ: Pearson correlation coefﬁ  cient.
Regression equation: LVMI change (WEND-Baseline) (ENA) = 6.8649 + 0.551855 *SBPMEAN24_CHANGE AT WENDVascular Health and Risk Management 2007:3(4) 379
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of ofﬁ  ce measurements which tend to be higher (Bobrie et al 
2005). Lastly, with the exception of LVMI, which was lower 
in this ancillary study, baseline characteristics were similar to 
those in the overall PICXEL study (Dahlöf et al 2005).
Because the correlations between changes in ambulatory 
BP and in LVMI were signiﬁ  cant in the enalapril group 
and non-signiﬁ  cant in the perindopril/indapamide group, 
the effect of perindopril/indapamide on LVMI seems to be 
not only pressure dependent. Different mechanisms can be 
postulated to explain the changes relatively independent 
from BP reduction in the perindopril/indapamide group. 
These mechanisms include the LV functional and structural 
improvement with perindopril (Grandi et al 1995). Another 
mechanism involving indapamide has been discussed in the 
main PICXEL study (Dahlöf et al 2005).
Conclusions
These data suggest that perindopril/indapamide has a sustained 
antihypertensive effect that decreases 24-hour and daytime 
SBP and PP as well as decreasing LVMI more effectively 
than enalapril. The results from this trial contribute to the 
growing pool of evidence that treatment with the combina-
tion perindopril/indapamide has signiﬁ  cant beneﬁ  cial effects 
on the cardiovascular health of a wide range of hypertensive 
patients including elderly and diabetic patients and patients 
with LVH (Chalmers et al 2000; Mogensen et al 2003; De 
Luca et al 2004; Dahlöf et al 2005). 
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